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Introduction: Periostin is a matricellular protein that is currently used as a biomarker for
asthma. However, its contribution to tissue remodeling in allergic asthma is currently
unknown. We have previously demonstrated that tissue-resident mesenchymal stem
cells known as pericytes are a key cell type involved in airway remodeling. This is thought
to be caused the uncoupling of pericytes from the microvasculature supporting the large
airways, facilitated by inflammatory growth factors and cytokines. It is hypothesized that
periostin may be produced by profibrotic pericytes and contribute to the remodeling
observed in allergic asthma.
Methods: Lung sections from mice with allergic airway disease driven by exposure
to house dust mite (HDM) were stained using an anti-periostin antibody to explore its
involvement in fibrotic lung disease. Human pericytes were cultured in vitro and stained
for periostin to assess periostin expression. Migration assays were performed using
human pericytes that were pretreated with TGF-β or periostin. ELISAs were also carried
out to assess periostin expression levels in bronchoalveolar lavage fluid as well as the
induction of periostin production by IL-13.
Results: Immunostaining indicated that pericytes robustly express periostin, with
increased expression following treatment with TGF-β. Migration assays demonstrated
that pericytes treated with periostin were more migratory. Periostin production was also
increased in HDM exposed mice as well as in cultured pericytes treated with IL-13.
Conclusion: Periostin is produced by pericytes in response to TGF-β or IL-13, and
periostin plays a key role in inducing pericyte migration. The increase in periostin
expression in TGF-β or IL-13 treated pericytes suggests that IL-13 may trigger periostin
production in pericytes whilst TGF-β modulates periostin expression to promote pericyte
migration in the context of tissue fibrosis.
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INTRODUCTION
Allergic asthma is a common, yet complex condition involving the constriction of airways, airway
wall thickening and overall reduction in airflow and increased airway hyperresponsiveness, driven
by a Type 2 immune response to inhaled allergens such as house dust mite, pet dander, and pollen
(1). The pathophysiology of asthma can be categorized by three aspects of airway remodeling:
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mucus hyperplasia, airway smooth muscle alterations, and
deposition of extracellular matrix (ECM) proteins. The causes of
remodeling are amuch contested topic, but the general consensus
is that myofibroblasts are responsible for the accumulation
of contractile elements and ECM proteins in the airway wall
(2–4). Pericytes are mesenchymal progenitor cells associated
with the tissue microvasculature, and have been shown in
organ fibrosis of varying etiology to be a primary source of
myofibroblasts (5–10). In healthy tissue, pericytes maintain the
structure and function of blood vessels and help control the
transport of cells and molecules in and out of the vasculature
(11). However, during inflammation-driven fibrosis, as observed
in allergic asthma, pericytes have been observed to uncouple from
capillaries within the airway wall and accumulate within and
around airway smooth muscle bundles, with elevated expression
of the myofibroblast marker α-smooth muscle actin (α-SMA)
and a demonstrable contribution to airway hyperactivity in
an allergen-driven model of allergic asthma (5). Additionally,
pericytes are also thought be the prime source of ECM proteins in
the lung and are major contributors to pulmonary fibrosis (12).
The complex interplay between inflammatory mediators that
results in the uncoupling and migration of pericytes is an
important area of investigation. By identifying the main driving
force in this process, pericyte migration could be inhibited or
even prevented, leading to improved lung function in allergic
asthma. One inflammatory mediator that deserves attention
is this regard is periostin, which is an extracellular matrix-
derived bioactive peptide (matrikine) that has recently been
implicated in Type 2-mediated tissue fibrosis (13, 14). Periostin is
a matricellular protein that was first identified as a cell adhesion
protein in 1993 (15). However, it is widely now associated with
fibrosis and other pro-fibrotic cytokines. It has strong links with
allergic asthma, with high serum levels of periostin being used
as a biomarker of asthma severity (16). It has also been strongly
linked to TGF-β, one of themost infamous pro-fibrotic cytokines,
as a co-regulatory relationship has been suggested between these
two mediators (17). This study aimed to identify the factors
that stimulate periostin expression by pericytes and elucidate the
contribution of periostin to airway remodeling in allergic asthma
by assessing the expression of periostin in an allergen-driven
mouse model of allergic airway disease (18, 19) and in cultured
human pericytes.
METHODS
In vivo House Dust Mite Model
Thirty female C57Bl/6 mice (6–8 weeks old) were purchased
from Charles River and housed at the Aston University central
animal facility under specific pathogen-free conditions. The mice
were provided with food and water and exposed to a 12-h
light-dark cycle. All mice were handled in compliance with UK
Home Office regulations on animal care and welfare (Animals
(Scientific Procedures) Act 1986). Allergic airway disease was
induced using a previously described protocol (19). In brief,
on 5 days per week over the course of five consecutive weeks,
mice (n = 15) were anesthetized with isoflurane (Sigma-Aldrich,
Missouri, USA) before being challenged with house dust mite
(HDM) allergen. HDM extract (Citeq, The Netherlands) was
suspended in sterile phosphate buffered saline (PBS; Sigma-
Aldrich) at a final concentration of 2.5 mg/ml. Ten microliters
of the solution was administered intranasally; control mice (n
= 15) received 10 µl of sterile PBS using the same protocol. All
animal experiments were carried out and recorded according to
the ARRIVE guidelines.
Scratch Assay
HPLPCs (human placental pericytes) from Promocell
(Heidelberg, Germany) were cultured until between passage
5–10 in pericyte-specific medium (Promocell) with 1%
antibiotic/antimycotic (ThermoFisher, Massachusetts, USA).
All cell culture was performed in well plates or flasks coated
with 2% gelatin powder (Sigma-Aldrich) in autoclaved distilled
water. Once a monolayer of pericytes was formed they were
treated with either 10 ng/ml TGF-β (Biolegend, California, USA),
100 ng/ml IL-13 (Biolegend), 100 ng/ml periostin (Biolegend)
or 1mM cinnamaldehyde (Sigma-Aldrich) for 48 h. A p200
pipette tip was used to scratch the monolayer and form a
wound once in each well. The cells were then washed with
PBS and transferred to serum-free low-glucose Dulbecco’s
Modified Eagle’s Medium (DMEM; Sigma-Aldrich) with 1%
antibiotic/antimycotic (Sigma-Aldrich) in order to arrest cell
proliferation. Images of each scratch were taken at 100x before
and after 24 h of incubation at 37◦C and 5% CO2. The area
of each scratch was calculated with ImageJ and the difference
between the areas before and after the incubation were used to
calculate the distance that was migrated.
Immunostaining
Immunostaining was performed on cultured human pericytes
(HPLPC; Promocell) and the large airways (tracheobronchial
wholemounts) and lung tissue from mice.
HPLPC were cultured as previously described on coverslips
coated in 2% gelatin. Cells were treated with 10 ng/ml TGF-
β or 100 ng/ml periostin for 5 days before having the medium
removed and being fixed with cold 100% ethanol for 10min.
Cells were then washed with PBS and blocked with 5% NGS
(normal goat serum; Sigma-Aldrich) in 0.3% Triton-X-100/PBS
for 60min. The primary antibodies against periostin raised in
rabbit (Abcam, Cambridge, UK; 1:200) and α-SMA raised in
mouse (directly conjugated with Cy3; Sigma-Aldrich; 1:1000)
were then added and incubated at room temperature for
60min before being removed and washed again with PBS. The
secondary antibody, AlexaFluor488 goat anti-rabbit (Invitrogen,
Gillingham, UK; 1:500), was then added and incubated for
60min. All antibodies were diluted in 0.3% Triton-X-100/PBS.
Following this, the antibodies were removed and the coverslips
were washed with PBS before being mounted with Fluoroshield
(Sigma-Aldrich) mounting medium containing DAPI.
Whole lungs and tracheas were taken from the mice
and stored in sucrose solution to cryopreserve the sample.
Sucrose was rinsed off using PBS. The large airways (trachea
and bronchi prepared and stained as a wholemount) were
cleaned of extraneous tissue and pinned down onto Sylgard-
coated plates (Sigma-Aldrich). Whole lungs were embedded in
Frontiers in Allergy | www.frontiersin.org 2 December 2021 | Volume 2 | Article 786034
Bignold and Johnson Periostin Promotes Pericyte Migration
TissueTek OCT (Sakura Finetech, Newbury, UK) and frozen
at −80◦C. Sections (10µm) were then cut using a cryostat
(Leica, Germany) and mounted on Superfrost Plus slides (Fisher
Scientific, Loughborough, UK). The slides were stored at−80◦C.
Prior to staining, slides were warmed to room temperature.
A hydrophobic marker was used to outline the tissue sections
before they were blocked with 5% NGS in 0.3% Triton-X-
100/PBS for 2 h. After this, the blocking solution was washed
off with PBS and the slides were incubated overnight at room
temperature with primary antibodies against periostin raised in
rabbit (Abcam), α-SMA raised in mouse (Abcam), or CD31
raised in Armenian hamster (Biolegend). Following incubation,
the primary antibody was washed off with PBS containing 0.3%
Triton-X, and the secondary antibody (AlexaFluor488 goat anti-
rabbit (Invitrogen), AlexaFluor555 goat anti-mouse (Invitrogen),
or AlexaFluor649 goat anti-hamster (Invitrogen) was added
and incubated again for 2 h. Slides were then washed again
with PBS and mounted using Fluoroshield with DAPI (Sigma-
Aldrich). Lung sections and tracheobronchial wholemounts were
imaged at the ARCHA Advanced Imaging Facility at Aston
University, employing a SP5 TCS II MP confocal microscope
(tracheobronchial wholemounts; Leica), an EVOSXLmicroscope
(ThermoFisher), or a widefield fluorescent microscope (Leica).
ELISA
Anti-periostin ELISAs (R&D Systems, Minnesota, US) were
performed on supernatant harvested from cultured HPLPCs
treated with 10 ng/ml TGF-β (Biolegend), 10 ng/ml EGF
(Biolegend), 10 ng/ml VEGF (Biolegend), 100 ng/ml IL-13
(Biolegend), 100 ng/ml periostin (Biolegend) or 0–2.5mM
cinnamaldehyde (Sigma-Aldrich) and on bronchoalveolar lavage
fluid harvested from HDM treated (and control) mice prepared
as previously described. All ELISAs were performed as per the
manufacturer’s instructions.
Statistical Analysis
All results are shown as mean ± standard deviation. GraphPad
Prism 8 was used for data processing and statistical analyses.
Differences were evaluated by Student’s t-test for two groups,
by one-way analysis of variance (ANOVA) for multiple groups
with the Tukey post-hoc test, or by two-way ANOVA with
Šídák’s multiple comparisons test as appropriate. Differences
were deemed to be statistically significant when a p-value <0.05
was obtained (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
RESULTS
Periostin Expression Is Increased in
Pericytes Following Chronic Aeroallergen
Exposure in Mice
Mice that had been subjected to 5 weeks of aeroallergen exposure
(Figure 1A) demonstrated robust peribronchial inflammation
with a high percentage of infiltrating eosinophils (Figures 1B,C),
indicating the establishment of a robust Th2 inflammatory
response to HDM exposure. The lung tissue was found to
express increased levels of periostin expression, particularly
in remodeled large airways, as compared to healthy control
lungs. As shown in Figure 1D (white arrow), robust periostin
expression was observed in the subepithelial region of the large
airways (bronchi and bronchioles). Conversely, the lungs of PBS-
exposed mice showed a very low level of periostin expression.
This was quantified through image analysis in ImageJ. where a
region of interest was selected at a consistent distance around
the airways and the density of positive periostin staining was
calculated. This analysis showed that the large airways of mice
that were exposed to HDM had significantly (p < 0.05) higher
expression of periostin the airways of healthy mice (Figure 1E).
The concentration of soluble periostin was measured by ELISA
in the bronchoalveolar lavage fluid of mice exposed to HDM and
control mice (Figure 1F), with a trend toward higher periostin
levels in mice exposed to HDM.
Further assessments of lung tissue stained for periostin
expression demonstrated that periostin was primarily
expressed by airway epithelial cells and pulmonary pericytes
(Figures 1D,G), with particularly robust expression observed
in pericytes that had uncoupled from the supporting
microvasculature (white arrows in Figures 1H,I). Similar
to what was observed in the subepithelial region of the large
airways in lung sections (Figure 1E), periostin expression was
significantly increased in the tracheobronchial whole mounts
(Figure 1J).
Type 2 Inflammatory Mediators Stimulate
Periostin Expression by Pericytes
Cultured pericytes were treated with the pro-fibrotic mediators
TGF-β and periostin in order to simulate the conditions of
fibrosis seen in allergic asthma. Untreated pericytes were found to
express low levels of periostin under control conditions, as seen
in Figure 2A. This production was increased following treatment
with TGF-β and periostin (Figure 2A) and quantified using
ImageJ (Figure 2B). Periostin treatment significantly increased
periostin production (p < 0.05), to a greater extent than TGF-
β treatment.
ELISAs were utilized to measure soluble periostin protein
secreted by pericytes treated with a number of profibrotic
mediators, selected to explore the relationship between these
inflammatory mediators, periostin expression, and fibrosis. Most
mediators did not induce the production of soluble periostin
in cultured pericytes, i.e., TGF-β, EGF, VEGF and periostin
(Figure 2C). Conversely, the supernatants from pericytes treated
with IL-13 contained a significantly higher concentration of
periostin (p < 0.0001), with an almost seven-fold increase.
Cultured pericytes were then treated with TGF-β or IL-13 and
assessed after 7 days or 9 days of exposure. Cells were stained
for periostin expression as well as the pericyte/mesenchymal cell
marker α-SMA (Figures 2D,E). In both treatments, periostin and
α-SMA expression were higher following 9 days of exposure to
both TGF-β and IL-13 compared to 7 days. Periostin expression
was similar following TGF-β and IL-13 treatment; however, TGF-
β treatment induced a much higher expression of α-SMA than
IL-13 treatment.
Type 2 Inflammatory Mediators Stimulate
Pericyte Migration
Figure 3A shows that treatment with TGF-β and periostin
significantly increased the migration of pericytes over 24 h. The
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FIGURE 1 | Periostin expression is increased following chronic aeroallergen exposure in mice. (A) Schematic diagram of HDM-induced allergic airway inflammation in
mice. (B) Female C57/Bl6 mice (6–8 weeks old) were exposed to either sterile PBS (10 µl intranasally) or house dust mite extract (HDM; 25 µg in 10 µL) 5 days a
week for five consecutive weeks. Hematoxylin and eosin stained lung sections from PBS and HDM-exposed mice. (C) Bronchoalveolar lavage fluid total cell counts
and percentage of eosinophils. (D) At the end of the allergen exposure protocol, lung sections obtained from PBS control and HDM-exposed mice were stained with
an anti-periostin antibody (green) and DAPI to stain nuclei (blue). Images were taken at 400x and 630x magnification as stated. Arrows indicate periostin positive cells.
(E) Expression of periostin was calculated in the area of interest around each airway using ImageJ. **p < 0.01, n = 3 representative of two independent experiments.
(F) Bronchoalveolar lavage samples were collected and the periostin content was assessed by ELISA. n = 4 representative of two independent experiments. (G,H)
Lung sections were stained for periostin (green), the pericyte marker PDGFRβ (red), and cell nuclei (DAPI, blue) to demonstrate the presence of periostin-expressing
pericytes around the airways and blood vessels of HDM-exposed mice. (I) Tracheobronchial whole mounts were stained for the mesenchymal cell marker α-smooth
muscle actin (α-SMA; red), the endothelial cell marker CD31 (cyan), and periostin (green) and imaged at 400x magnification; arrow indicate periostin-positive pericytes.
(J) The expression of periostin and α-SMA in tracheobronchial whole mounts was calculated using ImageJ. AW, airway; BV, blood vessel. **p < 0.01, n = 3–5
representative of two independent experiments.
images in Figure 3B are representative of each condition and
also show a decrease in the scratch width over 24 h. In these
images, the cells treated with TGF-β, periostin and IL-13 had a
smaller remaining scratch area than the untreated cells. As the
pericytes were incubated in serum-freemedium, cell proliferation
was arrested and therefore any increase in cell mass in the wound
was likely from pericytes that had moved into the scratch area.
Cinnamaldehyde Treatment Suppresses
Periostin Expression and Pericyte
Migration
Cinnamaldehyde (CIN) was explored as an IL-13 inhibitor to
reduce the effects of periostin, particularly on pericyte migration.
First, the effects of CIN on periostin production by IL-13 treated
pericytes were observed using ELISA to elucidate the optimum
concentration of CIN to use in further studies (Figure 4A).
Then, this concentration was used to treat cultured pericytes
alongside IL-13, periostin, and TGF-β to determine whether
CIN can prevent the migration of pericytes, assessed using the
scratch assay.
Between the concentrations 0–250µM, CIN had little effect
on the production of periostin in cells treated with IL-13 as the
concentration of periostin was maintained at around 7000 pg/ml,
similar to the pericytes that had been treated solely with IL-
13 (Figure 4A). However, at higher concentrations of CIN, i.e.,
1mM and 2.5mM, the concentration of periostin dropped below
the detection limit of the ELISA, suggesting that the IL-13 had
been successfully inhibited. Without IL-13, the pericytes failed to
produce any detectable levels of periostin at any concentration
of CIN.
As the lowest concentration of CIN to produce an inhibitory
effect was 1mM, this concentration was used in the migration
assay (Figure 4B). Treating pericytes with IL-13 and periostin
significantly increased the migration of pericytes (p < 0.01), as
previously shown in Figure 3. The addition of CIN to pericytes
treated with both IL-13 and periostin decreased the migration of
pericytes, with CIN significantly reducing the migration of IL-
13 treated pericytes (p < 0.05). There was no difference to the
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FIGURE 2 | Type 2 inflammatory mediators stimulate periostin expression by pericytes. (A,B) Immunostaining performed on pericytes grown in pericyte medium and
treated with 10 ng/ml of TGF-β or 100 ng/ml of periostin for 24 h. Cells were stained with an anti-periostin antibody (green) and the nuclear stain DAPI (blue). Images
were taken at 400x magnification and intensity of periostin stain was calculated with ImageJ. Intensity of stain per field of view was divided by the number of cells in
order to determine periostin expression per cell. *p < 0.05, n = 5 representative of two independent experiments. (C) Cultured pericytes were treated with 10 ng/ml
TGF-β, 10 ng/ml EGF, 10 ng/ml VEGF, 100 ng/ml IL-13 or 100 ng/ml Periostin in pericyte medium for 7 days before the supernatant was harvested. The periostin
content was assessed using an anti-periostin ELISA kit. ****p < 0.0001, n = 3 representative of two independent experiments. (D,E) Cultured pericytes were treated
with 10 ng/ml TGF-β or 100 ng/ml IL-13 for either 7 or 9 days. Cells were stained with an anti-periostin antibody and an anti-αSMA antibody. The images were taken at
400x magnification and quantifications were made using ImageJ. *p < 0.05, n = 3–4 representative of two independent experiments.
migration of pericytes treated with TGF-β with or without CIN;
similarly, CIN treatment alone had no effect on the migration
ability of untreated pericytes.
DISCUSSION
Periostin has been shown to contribute to several aspects of tissue
remodeling in allergic asthma (13, 16). Imaging periostin in situ
in fibrotic lung tissue indicated a layer of cells in the subepithelial
space of the airway that expressed periostin very strongly. As
these periostin expressing cells were not present in the lung
sections from healthy, PBS exposed mice, periostin evidently
contributes to the tissue remodeling seen around the large
airways in allergic asthma (5, 19). Previous studies have shown
that pericytes uncouple from the microvasculature supporting
the large airways and migrate into the smooth muscle layer of
the airway wall where they contribute to airway wall remodeling
and airway hyperresponsiveness following differentiation into
myofibroblasts (5, 20). In the present study, these uncoupling
PDGFRβ-positive pericytes in the airways of HDM-exposed
mice were found to highly express periostin, demonstrated
using both tracheobronchial whole mounts and lung sections
(Figures 1H,I), supporting the notion at periostin expression by
pericytes is associated with increased migratory capacity.
Periostin was also shown to be present in the bronchoalveolar
lavage fluid from mice exposed to HDM (Figure 1C). This
indicates that there was a large concentration of periostin
present in the inflamed lung, which may contribute to the
remodeling observed in allergic asthma. However, as this lavage
was collected from the airway lumen, it may not accurately depict
the levels of periostin within the subepithelial space where it
would interact with cells such as pericytes during the induction
of airway wall remodeling. However, serum periostin has been
investigated as a biomarker for eosinophilic inflammation and
airway remodeling in allergic asthma (16), supporting the notion
that elevated periostin levels in multiple body compartments is
a feature of allergic airway inflammation and remodeling. The
increase of periostin in both pericytes and epithelial cells in
the trachea (Figures 1I,J) and overall lung tissue of the lungs
of HDM-exposed mice justified further investigations into the
impact periostin on pericyte migration and differentiation into
myofibroblasts in vitro.
Cultured human pericytes were capable of producing high
levels of periostin under pro-fibrotic conditions (Figures 2A,B).
The production of periostin by pericytes is important as it
shows that pericytes are an important driver of the profibrotic
microenvironment and contribute to the cascade of mediators
that initiate fibrosis. These results (Figures 2A,B) also suggest
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FIGURE 3 | Type 2 inflammatory mediators stimulate pericyte migration. (A) Scratch assay performed on pericytes that were grown in pericyte medium and treated
with 10 ng/ml of TGF-β, 100 ng/ml of IL-13 or 100 ng/ml of periostin for 48 h. Cells were transferred into serum-free medium and a scratch was made in each
monolayer using a p200 pipette tip. (B) Images were taken at 100x magnification immediately after scratching and 24 h later. The scratch width was determined using
ImageJ and the average distance of cell migration was calculated. n = 6 representative of two independent experiments, *p < 0.05 vs. untreated cells.
a co-regulatory relationship between TGF-β and periostin, as
treatment with TGF-β also induced the production of periostin.
The data shown in Figure 2C confirms the suggestion that
IL-13 is the initiating factor of periostin production. This has
been described in several different cell types, such as epithelial
cells and fibroblasts, but has not yet been linked to pericytes
(13, 21). Treatment with any other of the tested cytokines did
not lead to the release of periostin by pericytes. We had already
demonstrated that TGF-β treatment increased the expression of
periostin in pericytes (Figures 2A,B), but elevated intracellular
expression of periostin did not translate into periostin release
from pericytes into the supernatant under these conditions.
Periostin has been observed in both the cytoplasm and the
extracellular matrix, which may indicate that it plays several
different roles depending on its location (22–24). Further studies
should be completed to explore the localization of periostin in
fibrotic conditions and the resulting effects on myofibroblast
migration, differentiation, and collagen deposition.
The contribution of periostin to enhanced pericyte migration
was shown in both Figures 3A,B, 4B. The migration of pericytes
is a key process in the initiation of airway fibrosis in response
to allergen exposure, as pericytes are required to uncouple
from the vasculature and migrate toward the airways in order
to contribute to the airway thickening and differentiation
into myofibroblasts (5). Studies in other organs, primarily in
the context of glioblastoma, have shown increased periostin
expression along with increased migratory capacity in pericytes,
as a mechanism driving angiogenesis during tumor growth
(25). By highlighting periostin as a possible contributing factor
to cell migration, this process may be targeted and arrested
early on. With both TGF-β and periostin having a similar
effect on pericyte migration in scratch assays, as shown in
Figure 3, this suggests that there is a relationship between
TGF-β and periostin as previously described by several other
groups (26, 27).
Cinnamaldehyde is a compound with antioxidant properties,
and has been shown to inhibit IL-13 activity (28). Thus,
cinnamaldehyde treatment was explored as a possible means
to reduce the amount of periostin present in the system and
thereby suppress its effects on pericytes and tissue fibrosis. The
impact of CIN was explored at different doses (Figure 4A)
in order to determine the optimum dose to achieve the
inhibition of periostin expression. As the concentration of IL-
13-induced periostin production dropped significantly at 1mM
CIN, this was the dose selected for subsequent experiments.
This concentration was then used to inhibit periostin-induced
pericyte migration (Figure 4B). There was a significant change
in the migratory behavior of IL-13-treated pericytes when CIN
was added, suggesting that CIN successfully blocked the activity
of IL-13 and its downstream effects on periostin expression
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FIGURE 4 | Cinnamaldehyde treatment suppresses periostin expression and pericyte migration. (A) Cultured pericytes were treated with 100 ng/ml IL-13 in pericyte
media for 7 days with the addition of cinnamaldehyde for the last 3 days at the concentration stated in (A) or only cinnamaldehyde at the stated concentration for 3
days. The supernatants were harvested and the periostin content was assessed by ELISA. **p < 0.01, ***p < 0.001 vs. the same cinnamaldehyde concentration
without IL-13, n = 2 representative of two independent experiments. (B) Scratch assay performed on pericytes that were grown in pericyte medium and treated with
10 ng/ml of TGF-β, 100 ng/ml of IL-13 or 100 ng/ml of periostin for 7 days with 1mM cinnamaldehyde added for the last 3 days. Cells were transferred into media
lacking serum and a scratch was made in each monolayer using a p200 pipette tip. Images were taken at 100x magnification immediately after scratching and 24 h
later. The scratch width was determined using ImageJ and the average distance of cell migration was calculated. n = 3 representative of two independent
experiments, 1 = p < 0.05 vs. the same growth factor treatment without cinnamaldehyde, *p < 0.05, **p < 0.01 vs. control treatment without cinnamaldehyde. (C)
Schematic diagram of the putative signaling pathways regulating periostin expression in pericytes (created using Biorender).
and pericyte migration. IL-13 treated pericytes also migrated
most effectively, which confirms that the sharp increase in
periostin production induces by IL-13 contributes to migration.
Periostin-treated pericytes also migrated effectively, although
CIN treatment only reduced this slightly, likely due to its
inhibitory step being further upstream. TGF-β treatment did
not have a considerable effect on pericyte migration, and this
was not impacted by CIN treatment. This may be due to
the fact that TGF-β also stimulates pericyte differentiation
into myofibroblasts, as previously demonstrated in pericytes
derived from the kidney, i.e., mesangial cells (29). Thus,
our experiments suggest that IL-13 and TGF-β cooperatively
increase periostin expression and secretion by pericytes. After
secretion, periostin subsequently enhances pericyte migratory
capacity and TGF-β expression, likely via integrin αvβ3,
representing a critical positive feedback loop in the induction
of airway remodeling in response to allergic inflammation.
The putative signaling pathways involved in increased pericyte
migration in response to IL-13, TGF-β, and periostin are
shown in Figure 4C. Studies are underway to explore this
further in pulmonary pericytes in the context of allergic
airway inflammation.
This study has several important limitations. First the
causality of elevated periostin expression as a driver of increased
pericyte migration has not been conclusively demonstrated.
Experiments employing periostin knockout/knockdown
strategies should be performed to explore this hypothesis.
Second, the reversibility of periostin overexpression in the
lungs of mice exposed to allergen has not yet been explored,
which may be informative when considering targeting periostin
expression therapeutically. Finally, the in vitro experiments
were performed on placental pericytes (which are commercially
available) rather than human pulmonary pericytes, owing to the
difficulty of obtaining fresh human lung specimens during the
COVID-19 pandemic. Future work in this field should explore
the similarities and differences in pericytes from different organs.
CONCLUSION
Periostin is an often overlooked, yet important mediator in
fibrosis and, in particular, allergic asthma. Pericytes have been
shown to actively produce periostin in a profibrotic environment
both in vitro and in vivo. This study has demonstrated that the
production of periostin is initiated by IL-13, a Type 2 cytokine
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with well-known roles in allergic asthma. Elevated periostin
levels were found to promote the migration of pericytes, a
key event in airway wall remodeling in allergic airway disease.
This increased migration was prevented by the addition of
cinnamaldehyde, an IL-13 inhibitor that shows promise as a
future pharmaceutical intervention. Further studies should be
completed in order to test the full capabilities of cinnamaldehyde
as well as to elucidate the full effects of IL-13 and periostin in the
fibrotic lung.
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